PSMA-PET to Guide Prostatectomy

Prior treatment

• Participation in another investigational trial involving research exposure to ionizing radiation concurrently or within 30 days.
• Does not meet safety criteria for MRI scan (e.g. metal implant that is not allowed, since MRI is required for comparison).

Other illness

• Significant acute or chronic medical, neurologic, or illness in the subject that, in the judgment of the Principal Investigator, could compromise subject safety, limit the ability to complete the study, and/or compromise the objectives of the study.

• Significant prostate cancer:
  • Gleason 3+4 ≥1 core with pattern 4 ≥20%
  • Gleason 3+4 ≥1 core with ≥50% total involvement of core OR ≥3 cores of Gleason 3+4 OR
  • NCCN unfavorable intermediate risk OR
  • Any Gleason 4+3, 4+4, 4+5, 5+4, or 5+5 AND
• Baseline sexual function (IIEF-EF \> 17): No erectile dysfunction OR mild-to- moderate erectile dysfunction (International Index of Erectile Function Domain ≥ 17) AND
• The patient desires to maintain erections following treatment
• Planned to undergo a standard of care MRI or recently completed standard of care MRI within 6 months of scheduled date of surgery. Note: For subjects whose SOC MRI is not within 6 months or not 3Tesla, they may be enrolled in the study and the MRI will be repeated as a research study. The research MRI will not be billed to the subject's insurance, but will be scheduled at IU ORI, at no cost to study participant.
• Planned Prostatectomy candidate per treating oncologist with prostatectomy planned within 90 days of consent.